This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Company News for Mar 2, 2026
by Zacks Equity Research
Companies in The News Are: BCS, XYZ, INTU, CGON
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
by Zacks Equity Research
CGON expects phase III PIVOT-006 top-line data in first-half 2026, nearly a year early, after enrollment finished ahead of schedule across more than 90 sites.
Company News for Nov 17, 2025
by Zacks Equity Research
Companies in The News Are: SR,CGON,GLOB,NU
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of 0.00% and +412.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of -20.00% and -60.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?
by Zacks Equity Research
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last?
by Zacks Equity Research
CG Oncology, Inc. (CGON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
by Zacks Equity Research
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
Company News for May 14, 2025
by Zacks Equity Research
Companies in The News Are: UAA,LSTR,SLAB,CGON